Table 2.

Adverse Events

	No. (%) of Patients (n = 9)
Adverse Event	Grade 3	Grade 4	Grade 5
Possibly related
Central nervous system
Intracranial hemorrhage	1 (11%)	0 (0%)	0 (0%)
Unrelated
Central nervous system
Ischemic stroke	1 (11%)	0 (0%)	0 (0%)
Brain edema, localized	1 (11%)	0 (0%)	0 (0%)
Epileptic seizure	2 (22%)	0 (0%)	0 (0%)
Hemiparesis	2 (22%)	0 (0%)	0 (0%)
Aphasia	1 (11%)	0 (0%)	0 (0%)
Meningitis	1 (11%)	0 (0%)	0 (0%)
Others
Increased liver enzymes	1 (11%)	0 (0%)	0 (0%)

All Adverse Events (AEs; including Severe Adverse Events) CTCAE grade ≥3 from all evaluable patients according to their causal relationship to the study product and study-related procedures as evaluated by the Data and Safety Monitoring Board (DSMB) of the CAR2BRAIN study.